{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:40:28Z","timestamp":1787319628494,"version":"build-2736575974"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Wolfe Medical Research Chair in Pharmacogenomics"},{"name":"Ontario Research Fund-Research Excellence"},{"name":"Western University Department of Medicine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to determine the correlation between tissue and plasma infliximab concentrations in an outpatient ulcerative colitis (UC) cohort based on histologic disease activity in addition to their relationship with long-term clinical outcomes. We assessed intraparticipant variability in infliximab concentrations between adjacent intestinal samples and the correlation between disease activity and tumor necrosis factor-\u03b1 (TNF-\u03b1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective cohort study was conducted in participants with UC receiving infliximab. Blood and 2 sigmoid colon biopsies were obtained at the index colonoscopy for infliximab and TNF-\u03b1 quantification. Histological disease activity was assessed. Participants were followed for 2 years for the occurrence of hospitalization, surgery, disease relapse, and infliximab discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A positive correlation was observed between mean plasma and uninflamed tissue infliximab concentrations only (Rs\u2005=\u20050.75, P\u2005=\u2005.0071). Lower mean tissue infliximab concentrations correlated with a shorter time to disease relapse vs those with higher mean tissue concentrations (Rs\u2005=\u20050.77, P\u2005=\u2005.032). This was not seen when using plasma infliximab concentrations. Additionally, no significant intraparticipant variability of infliximab concentrations was observed for all participants independent of disease activity. Neither plasma nor tissue TNF-\u03b1 correlated with disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings support data generated in patients with Crohn\u2019s disease: plasma infliximab concentrations are reflective of infliximab exposure in tissue in the UC patient in remission, but not for those with active disease. Increasing tissue concentrations in the noninflamed tissues may improve durability of infliximab. Neither plasma nor tissue TNF-\u03b1 appear to correlate with UC disease activity. Larger follow-up studies would be of benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izae097","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T19:17:05Z","timestamp":1712949425000},"page":"2174-2180","source":"Crossref","is-referenced-by-count":4,"title":["Infliximab Tissue Concentrations in Patients With Stable Ulcerative Colitis Are Correlated With More Durable Infliximab-associated Disease Remission"],"prefix":"10.1093","volume":"30","author":[{"given":"John","family":"Choi","sequence":"first","affiliation":[{"name":"Department of Physiology and Pharmacology, Western University , Medical Sciences Building, Rm 216, London, ON, N6A 5C1 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine and Dentistry, Western University , Health Sciences Addition Building, Room H3 and H4, London, ON, N6A 5C1 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Beaton","sequence":"additional","affiliation":[{"name":"Divisions of Gastroenterology, Clinical Pharmacology, Western University , 339 Windermere Rd, London, ON, N6A 5A5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Western University , Medical Sciences Building, Rm 216, London, ON, N6A 5C1 ,","place":["Canada"]},{"name":"Department of Medicine, Western University , 339 Windermere Rd, London, ON, N6A 5A5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Khanna","sequence":"additional","affiliation":[{"name":"Divisions of Gastroenterology, Clinical Pharmacology, Western University , 339 Windermere Rd, London, ON, N6A 5A5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6568-1714","authenticated-orcid":false,"given":"Aze","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Western University , Medical Sciences Building, Rm 216, London, ON, N6A 5C1 ,","place":["Canada"]},{"name":"Divisions of Gastroenterology, Clinical Pharmacology, Western University , 339 Windermere Rd, London, ON, N6A 5A5 ,","place":["Canada"]},{"name":"Department of Medicine, Western University , 339 Windermere Rd, London, ON, N6A 5A5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"issue":"21","key":"2024110408183790000_CIT0001","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N Engl J Med."},{"issue":"7152","key":"2024110408183790000_CIT0002","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature."},{"issue":"0","key":"2024110408183790000_CIT0003","doi-asserted-by":"crossref","first-page":"493012","DOI":"10.1155\/2015\/493012","article-title":"Inflammatory bowel disease: an overview of immune mechanisms and biological treatments","volume":"2015","author":"de Mattos","year":"2015","journal-title":"Mediators Inflamm."},{"issue":"11","key":"2024110408183790000_CIT0004","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1080\/00365520701409035","article-title":"Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis","volume":"42","author":"Olsen","year":"2007","journal-title":"Scand J Gastroenterol."},{"issue":"10","key":"2024110408183790000_CIT0005","doi-asserted-by":"crossref","first-page":"2040622319838443","DOI":"10.1177\/2040622319838443","article-title":"Infliximab in inflammatory bowel disease","volume":"10","author":"Papamichael","year":"2019","journal-title":"Ther Adv Chronic Dis"},{"issue":"4","key":"2024110408183790000_CIT0006","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol."},{"issue":"23","key":"2024110408183790000_CIT0007","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med."},{"issue":"0","key":"2024110408183790000_CIT0008","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.14309\/00000434-200509001-00789","article-title":"Infliximab results in reduction of inflammation and inflammatory markers in the mucosa of ulcerative colitis patients: the act 1 trial: 789","volume":"100","author":"Geboes","year":"2005","journal-title":"Am J Gastroenterol."},{"issue":"9","key":"2024110408183790000_CIT0009","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"2024110408183790000_CIT0010","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.cgh.2014.07.029","article-title":"Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab","volume":"13","author":"Yanai","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"2024110408183790000_CIT0011","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/gutjnl-2014-308099","article-title":"The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the atlas study","volume":"65","author":"Yarur","year":"2015","journal-title":"Gut."},{"issue":"12","key":"2024110408183790000_CIT0012","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1097\/MIB.0000000000001260","article-title":"Tissue drug concentrations of anti-tumor necrosis factor agents are associated with the long-term outcome of patients with Crohn\u2019s disease","volume":"23","author":"Yoshihara","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2024110408183790000_CIT0013","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ajg.2011.103","article-title":"Assessing response and loss of response to biological therapies in ibd","volume":"106","author":"Yanai","year":"2011","journal-title":"Am J Gastroenterol."},{"issue":"12","key":"2024110408183790000_CIT0014","first-page":"656","article-title":"Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease","volume":"15","author":"Fine","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"2","key":"2024110408183790000_CIT0015","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology."},{"issue":"11","key":"2024110408183790000_CIT0016","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1093\/ibd\/izz202","article-title":"Infliximab and adalimumab concentrations may vary between the enzyme-linked immunosorbent assay and the homogeneous mobility shift assay in patients with inflammatory bowel disease: a prospective cross-sectional observational study","volume":"25","author":"Clarke","year":"2019","journal-title":"Inflamm Bowel Dis."},{"issue":"12","key":"2024110408183790000_CIT0017","doi-asserted-by":"crossref","first-page":"616","DOI":"10.20452\/pamw.1537","article-title":"TNF-\u03b1 and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn\u2019s disease and ulcerative colitis","volume":"122","author":"Owczarek","year":"2012","journal-title":"Polskie Archiwum Medycyny Wewn\u0119trznej= Polish Archives of Internal Medicine"},{"issue":"2","key":"2024110408183790000_CIT0018","first-page":"211","article-title":"Tumor necrosis factor-alpha serum level in assessment of disease activity in inflammatory bowel diseases","volume":"10","author":"Avdagic","year":"2013","journal-title":"Med Glas (Zenica)"},{"issue":"1","key":"2024110408183790000_CIT0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000508069","article-title":"Plasma oncostatin m, TNF-\u03b1, il-7, and il-13 network predicts crohn\u2019s disease response to infliximab, as assessed by calprotectin log drop","volume":"39","author":"Mateos","year":"2021","journal-title":"Dig Dis."},{"issue":"1","key":"2024110408183790000_CIT0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s005350050218","article-title":"Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis","volume":"34","author":"Ishiguro","year":"1999","journal-title":"J Gastroenterol."},{"issue":"3","key":"2024110408183790000_CIT0021","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ibd.20759","article-title":"Quantitive cytokine MRNA expression profiles in the colonic mucosa of patients with steroid naive ulcerative colitis during active and quiescent disease","volume":"15","author":"Matsuda","year":"2009","journal-title":"Inflamm Bowel Dis."},{"issue":"7","key":"2024110408183790000_CIT0022","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/ibd\/izac169","article-title":"Ustekinumab tissue and serum levels in patients with Crohn\u2019s disease are closely correlated though not consistently associated with objective response after induction","volume":"29","author":"Proietti","year":"2023","journal-title":"Inflamm Bowel Dis."},{"issue":"11","key":"2024110408183790000_CIT0023","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/ibd\/izab053","article-title":"Vedolizumab tissue concentration correlates to mucosal inflammation and objective treatment response in inflammatory bowel disease","volume":"27","author":"Pauwels","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"2024110408183790000_CIT0024","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/ecco-jcc\/jjaa239","article-title":"Tissue exposure does not explain nonresponse in ulcerative colitis patients with adequate serum vedolizumab concentrations","volume":"15","author":"Van den Berghe","year":"2020","journal-title":"J Crohns Colitis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/11\/2174\/59882222\/izae097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/11\/2174\/59882222\/izae097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T03:18:54Z","timestamp":1730690334000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/30\/11\/2174\/7667169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,5,8]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae097","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,5,8]]}}}